

## WHAT IS CLAIMED IS:

1. A formulation comprising:

- i. an anti-Respiratory Syncytial Virus (RSV) F protein monoclonal antibody;  
and
- ii. an ionic excipient;

wherein the monoclonal antibody is present at a concentration of about 50mg/ml or greater,  
wherein the ionic excipient comprises lysine hydrochloride at a concentration of about 75 mM to about 120 mM or arginine hydrochloride at a concentration of about 75 mM to about 120 mM,

wherein the monoclonal antibody has a pI in the range of pH 6.0 to pH 7.5,

wherein the formulation has a pH of about 5.5 to about 7.5, and

wherein the monoclonal antibody has light chain CDR sequences:

CDR-L1 of SEQ ID NO: 3

CDR-L2 of SEQ ID NO: 4

CDR-L3 of SEQ ID NO: 5

and heavy chain CDR sequences:

CDR-H1 of SEQ ID NO: 6

CDR-H2 of SEQ ID NO: 7

CDR-H3 of SEQ ID NO: 8.

2. A formulation according to any one of the preceding claims, wherein the monoclonal antibody has a light chain variable region sequence of SEQ ID NO: 9 and a heavy chain variable region sequence of SEQ ID NO: 10.
3. A formulation according to any one of the preceding claims, wherein the monoclonal antibody has a light chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ ID NO: 2.
4. A formulation according to any one of the preceding claims, wherein the monoclonal antibody is present in the formulation at a concentration of about 100 mg/ml.

5. A formulation according to any one of the preceding claims, wherein the formulation has a pH in the range of about pH 5.7 to about pH 6.1.
6. The formulation according to claim 5, wherein the formulation has a pH of about pH 6.0.
7. A formulation according to any one of the preceding claims, wherein the ionic excipient comprises arginine hydrochloride at a concentration of about 75 mM to about 100 mM.
8. The formulation according to claim 7, wherein the ionic excipient comprises arginine hydrochloride at a concentration of about 80 mM.
9. A formulation according to any one of the preceding claims, wherein the formulation further comprises a sugar.
10. The formulation according to claim 9, wherein the sugar is sucrose.
11. A formulation according to claim 9 or 10, wherein the sugar is present at a concentration of about 100 mM to about 140 mM.
12. The formulation according to claim 11, wherein the sugar is present at a concentration of about 120 mM.
13. A formulation according to any one of the preceding claims, wherein the formulation further comprises one or more buffers selected from histidine, histidine hydrochloride, and histidine/ histidine hydrochloride.
14. A formulation according to claim 13, wherein the one or more buffers is L-histidine/ L-histidine hydrochloride monohydrate.

15. A formulation according to claim 13 or 14, wherein the one or more buffers is present at a concentration of about 10 mM to about 50 mM.
16. The formulation according to claim 15, wherein the one or more buffers is present at a concentration of about 30 mM
17. A formulation according to any one of the preceding claims, wherein the formulation further comprises a surfactant.
18. The formulation according to claim 17, wherein the surfactant comprise a polysorbate.
19. The formulation according to claim 18, wherein the polysorbate comprises polysorbate-80.
20. A formulation according to claim 17, 18 or 19, wherein the surfactant is present in the formulation at a concentration from about 0.001 % (w/v) to about 0.07 % (w/v).
21. The formulation according to claim 20, wherein the surfactant is present in the formulation at a concentration from about 0.02 % (w/v) to about 0.04 % (w/v).
22. A formulation comprising:  
an anti-Respiratory Syncytial Virus (RSV) F protein monoclonal antibody; and  
an ionic excipient;  
wherein the anti-RSV monoclonal antibody comprises the MEDI 8897 monoclonal antibody having a light chain of SEQ ID NO: 1 and a heavy chain of SEQ ID NO: 2;  
wherein the MEDI 8897 monoclonal antibody has a pI of pH 6.0 to pH 7.5;  
wherein the monoclonal antibody is present at a concentration of 75 mg/ml to 200 mg/ml;  
wherein the ionic excipient comprises arginine hydrochloride at a concentration of 75 mM to 100 mM;  
wherein the formulation further comprises 10 mM to 50 mM L-histidine/L-histidine hydrochloride monohydrate, 100 mM to 140 mM sucrose, and 0.02% to 0.04% (w/v) polysorbate 80; and  
wherein the formulation has a pH of 5.7 to 6.1.

23. A formulation comprising a monoclonal antibody that specifically binds the Respiratory Syncytial Virus (RSV) F protein and an ionic excipient;
- wherein the monoclonal antibody has a pI of pH 6.0 to pH 7.5;
  - wherein the monoclonal antibody is present at a concentration of 75 mg/ml to 100 mg/ml;
  - wherein the ionic excipient comprises arginine hydrochloride at a concentration of 75 mM to 100 mM;
  - wherein the formulation further comprises 10 mM to 50 mM L-histidine/L-histidine hydrochloride monohydrate, 100 mM to 140 mM sucrose, and 0.02% to 0.04% (w/v) polysorbate 80;
  - wherein the formulation has a pH of 5.7 to 6.1; and
  - wherein the monoclonal antibody comprises a light chain comprising a CDR-L1 sequence of QASQDIVNYLN (SEQ ID NO: 3), a light chain CDR-L2 sequence of VASNLET (SEQ ID NO: 4), and a light chain CDR-L3 sequence QQYDNLPLT of (SEQ ID NO: 5) and a heavy chain comprising a CDR-H1 sequence of DYIIN (SEQ ID NO: 6), a CDR-H2 sequence of GIIPVLGTVHYGPKFQG (SEQ ID NO: 7), and a CDR-H3 sequence of ETALVVSETYLPHYFDN (SEQ ID NO: 8).
24. A formulation according to claim 23, wherein the monoclonal antibody has a light chain variable region sequence of SEQ ID NO: 9 and a heavy chain variable region sequence of SEQ ID NO: 10.
25. A formulation according to any one of the preceding claims, wherein the wherein the monoclonal antibody has a pI that overlaps with the pH of the formulation.
26. A formulation according to any one of the preceding claims, wherein the monoclonal antibody is an IgG1 monoclonal antibody.
27. A formulation according to any one of the preceding claims, wherein the formulation further comprises one or more additional excipients, including for example, one or more sugars, salts, amino acids, polyols, chelating agents, emulsifiers and/or preservatives.

28. A formulation according to any one of the preceding claims, which is a pharmaceutical formulation.
29. The pharmaceutical formulation according to claim 28 for use as a medicament.
30. The pharmaceutical formulation according to claim 28 for use in the treatment of a disease.
31. The pharmaceutical formulation according to claim 28 for use in the treatment or prevention of a disease in a subject, wherein the pharmaceutical formulation is to be administered to the subject.
32. The formulation of any one of claims 1 to 31, wherein the formulation is liquid.
33. The formulation of any one of claims 1 to 31, wherein the formulation is lyophilized.
34. Use of a pharmaceutical formulation according to claim 28 in the manufacture of a medicament for the treatment or prevention of a disease in a subject, wherein the medicament is to be administered to the subject.
35. A lyophilized cake capable of being reconstituted using only sterile water into a formulation as defined in any one of claims 1 to 31.
36. A composition capable of being lyophilized to form a lyophilized cake, wherein the lyophilized cake is capable of being reconstituted using only sterile water into a formulation as defined in any one of claims 1 to 31.